Multiple effects of bevacizumab in angiogenesis: Implications for its use in age-related macular degeneration

Acta Ophthalmologica

Volumn 87, Issue 5, 2009, Pages 517-523

  Carneiro, Angela ^a,b   Falcão, Manuel ^a,b   Azevedo, Isabel ^a   Falcão Reis, Fernando ^a,b   Soares, Raquel ^a  

^a University of Porto   (Portugal)

^b HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

AMD; Angiogenesis; Anti VEGF; Avastin; Choroidal neovascularization; Endothelium; HUVEC

Indexed keywords

BEVACIZUMAB; HEMOGLOBIN; MATRIGEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CAPILLARY; CELL ASSAY; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NICK END LABELING; NONHUMAN; OCULAR BLOOD VESSEL; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; UMBILICAL VEIN;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; CAPILLARIES; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; COLLAGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; HEMOGLOBINS; HUMANS; LAMININ; MACULAR DEGENERATION; MICE; MICE, NUDE; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEOGLYCANS; UMBILICAL VEINS;

EID: 70350506087     PISSN: 1755375X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2008.01257.x     Document Type: Article

References (32)

1. Costa C, Incio J Soares R (2007 Angiogenesis and chronic inflammation: cause or consequence? Angiogenesis 10 : 149 166.
2. Drabkin DS Ausin JH (1932 Spectrophotometric constants for common haemoglobin derivatives in human, dog and rabbit blood. J Biol Chem 98 : 719 728.
3. European Medicines Agency (2005 Scientific Discussion. http://www.emea.europa.eu/humandocs/PDFs/EPAR/avastin/17199204en6.pdf.
4. Ferrara N, Hillan KJ, Gerber HP Novotny W (2004 Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 23 : 391 400.
5. Ferrara N, Damico L, Shams N, Lowman H, Kim R (2006 Development of ranibizumab, an anti-vascular endothelial growth factor antigen-binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26 : 859 870.
6. Gariano RF Gardner T (2005 Retinal angiogenesis in development and disease. Nature 438 : 960 966.
7. Gragoudas E, Adamis A, Cunningham E, Feinsod M, Guyer DR the VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group (2004 Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351 : 2805 2816.
8. de Jong PT (2006 Age-related macular degeneration. N Engl J Med 355 : 1474 1485.
9. ® treatment. Acta Ophthalmol 86 : 456 458.
10. Manzano R, Peyman G, Khan P Kivilcim M (2006 Testing intravitreal toxicity of bevacizumab (Avastin). Retina 26 : 257 261.
11. Maturi R, Bleau L Wilson D (2006 Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 26 : 270 274.
12. Melo GB, Farah ME Aggio FB (2007 Intravitreal injection of bevacizumab for cystoid macular oedema in retinitis pigmentosa. Acta Ophthalmol Scand 85 : 461 463.
13. ®) in proliferative diabetic retinopathy. Acta Ophthalmol Scand (in press).
14. Pedersen R, Soliman W, Lund-Andersen H Larsen M (2007 Treatment of choroidal neovascularization using intravitreal bevacizumab. Acta Ophthalmol Scand 85 : 526 533.
15. Quiram PA, Hassan TS Williams GA (2007 Treatment of naive lesions in neovascular age-related macular degeneration with pegaptanib. Retina 27 : 851 856.
16. Rocha A, Azevedo I Soares R (2007 Progesterone sensitizes breast cancer MCF7 cells to imatinib inhibitory effects. J Cell Biochem. 103 : 607 614.
17. ®) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36 : 331 335.
18. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, Miller JW, Haller JA, Reimann JD, Greene WL Shams N (2005b Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 112 : 1048 1053.
19. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY MARINA Study Group (2006 Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 : 1419 1431.
20. Saif MW Mehra R (2006 Incidence and management of bevacizumab-related toxicities in colorectal cancer. Expert Opin Drug Saf 5 : 553 566.
21. Shah MA, Ilson D Kelsen DP (2005 Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy. J Clin Oncol 23 : 2574 2576.
22. Shahar J, Avery R, Heilweil G et al. (2006 Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 26 : 262 269.
23. Shima C, Sakaguchi H, Gomi F et al. (2007 Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol Scand (in press).
24. Shojaei F Ferrara N (2007 Antiangiogenesis to treat cancer and intraocular neovascular disorders. Lab Invest 87 : 227 230.
25. Soares R, Balogh G, Guo S, Gärtner F, Russo J Schmitt F (2004 Evidence for the notch signalling pathway on the role of oestrogen in angiogenesis. Mol Endocrinol 18 : 2333 2343.
26. Soliman W, Vinten M, Sander B, Soliman KA, Yehya S, Rahman MS Larsen M (2008 Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema. Acta Ophthalmol 86 : 365 371.
27. Spandau UH, Ihloff AK Jonas JB (2006 Intravitreal bevacizumab treatment of macular oedema due to central retinal vein occlusion. Acta Ophthalmol Scand 84 : 555 556.
28. Spitzer MS, Wallenfels-Thilo B, Sierra A et al. (2006 Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol 90 : 1316 1321.
29. Steinbrook R (2006 The price of sight - ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 355 : 1409 1412.
30. Wang Y, Fei D, Vanderlaan M Song A (2004 Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7 : 335 345.
31. Yoeruek E, Ziemssen F, Henke-Fahle S, Tatar O, Tura A, Grisanti S, Bartz-Schmidt KU, Szurman P Tübingen Bevacizumab Study Group (2008 Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta Ophthalmol 86 : 322 328.
32. Ziemssen F, Folprecht G Ziemssen T (2007 Intravitreous bevacizumab and blood pressure: does 'safe' mean 'safe enough'? Acta Ophthalmol Scand 85 : 573 574.